Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholecystitis01:20

Cholecystitis

Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
Gallbladder01:17

Gallbladder

The gallbladder is a small, pear-shaped organ that plays a crucial role in our digestive system. Measuring about 10 cm in length, it is comparable in size to a kiwi fruit and is located in a hollow area on the lower surface of the liver. The gallbladder's primary function is to store and concentrate bile, a fluid produced by the liver that aids in digestion.
The gallbladder's anatomy consists of three regions: the fundus, body, and neck. Extending from the neck, the cystic duct joins the common...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of smoking cessation on survival and treatment tolerability in advanced non-small cell lung cancer: a single-center experience from Morocco.

Ecancermedicalscience·2026
Same author

Biomarker-Guided Adjuvant Therapy in Stage II/III Colon Cancer: A Systematic Review of Current Evidence and Clinical Implications.

Cancer investigation·2026
Same author

Rethinking biomarker strategy in gastric cancer immunotherapy: from tumor to host.

Frontiers in immunology·2026
Same author

PARP Inhibitors in Metastatic Prostate Cancer: Bridging Biomarker Complexity and Clinical Decision-Making Through a Pragmatic Treatment Framework.

Cancers·2026
Same author

The oncogeriatric transition in Morocco: health-system challenges and strategic priorities in an aging society.

Frontiers in public health·2026
Same author

Post-neoadjuvant and peri-operative ctDNA-defined minimal residual disease in triple-negative breast cancer: a systematic review and meta-analysis.

Breast cancer research and treatment·2026

Related Experiment Video

Updated: Jun 6, 2026

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma
05:22

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Published on: February 13, 2026

[Chemotherapy in gallbladder carcinoma].

Halima Abahssain1, Pauline Afchain, Nawfal Melas

  • 1Institut national d'oncologie, service d'oncologie médicale, 10100 Rabat, Maroc. abahssainhalima@yahoo.fr

Presse Medicale (Paris, France : 1983)
|November 16, 2010
PubMed
Summary

Gallbladder cancer (GBC) is aggressive, with surgery for localized stages. Gemcitabine plus cisplatin shows survival benefits for advanced bile tract cancer, offering a new treatment direction.

More Related Videos

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Related Experiment Videos

Last Updated: Jun 6, 2026

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma
05:22

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Published on: February 13, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Area of Science:

  • Oncology
  • Gastroenterology

Background:

  • Gallbladder cancer (GBC) is an aggressive malignancy with variable geographic incidence.
  • Current treatment for localized GBC is surgery, but advanced or metastatic disease lacks a standard therapeutic approach.
  • Research often combines GBC with other biliary tract cancers (BTC), leading to a scarcity of GBC-specific studies and limited high-quality randomized trials.

Purpose of the Study:

  • To review the current landscape of gallbladder cancer treatment.
  • To highlight the efficacy of gemcitabine (GEM) plus cisplatin (CDDP) in advanced bile tract cancers.
  • To explore the potential of targeted therapies based on molecular understanding of GBC carcinogenesis.

Main Methods:

  • Review of existing literature on gallbladder cancer and biliary tract cancer treatment.
  • Analysis of findings from key clinical trials, including the ABC-02 trial.
  • Discussion of molecular mechanisms driving GBC development.

Main Results:

  • The ABC-02 trial demonstrated a survival benefit for gemcitabine (GEM) plus cisplatin (CDDP) in advanced BTC, establishing it as a standard treatment.
  • Adjuvant therapy following surgical resection for GBC remains unvalidated.
  • Molecular insights into GBC carcinogenesis are paving the way for targeted therapeutic strategies.

Conclusions:

  • Gemcitabine plus cisplatin is the current standard for advanced BTC.
  • Further research into GBC-specific molecular pathways is crucial for developing effective targeted therapies.
  • Targeted therapies hold promise for improving survival and quality of life in GBC patients.